Skip to Content


Rating as of

Morningstar’s Analysis

Currency in USD
Is it the right time to buy or sell?
Find out with Morningstar Premium
Is it the right time to buy or sell?
Find out with Morningstar Premium

1-Star Price


5-Star Price


Economic Moat


About Quantitative Ratings

Morningstar Quantitative ratings for equities (denoted on this page by) are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings. Companies withratings are not formally covered by a Morningstar analyst, but are statistically matched to analyst-rated companies, allowing our models to calculate a quantitative moat, fair value, and uncertainty rating. Click here for more on how to use these ratings.

Company Profile

Business Description

Virbac SA is a major drug manufacturing company with a focus on animal health. The company generates the vast majority of its revenue in Europe, followed by North America and Latin America. Most of the company's sales are generated from its Companion Animals segment, followed by its Food Producing Animals segment. Veterinarians remain Virbac's main client, yet the company's clients are particularly diverse throughout the world in terms of profession, size and expectations. Virbac's strategy focuses on dominating niche markets while either avoiding or remaining differentiated within the more competitive markets.

2065m LID, 1 ere avenue
Carros, 06516, France
Sector Healthcare
Industry Drug Manufacturers - General
Most Recent Earnings
Fiscal Year End Dec 31, 2020
Stock Type
Employees 4,900